Last updated: April 24, 2026
What companies supply Sodium Iodide I-123 (I-123) production and distribution?
Sodium iodide I-123 is supplied through two channels: (1) manufacturers that produce iodine-123 (radioisotope production, often at cyclotron target facilities) and (2) nuclear medicine radiopharmacy distributors that prepare and supply the clinically labeled “sodium iodide I-123” product to end users.
The market is dominated by vertically integrated radioisotope producers and dedicated radiopharmacy logistics/distribution networks. For business planning, the practical supplier set for “sodium iodide I-123” is the set of companies that (a) distribute I-123 clinically labeled vials and (b) support standard nuclear medicine handling and shipping.
Which named suppliers are consistently in the I-123 supply chain?
The table below lists suppliers that are publicly associated with radioisotope production and/or distribution of iodine-123 products used in nuclear medicine.
| Supplier / entity |
Supplier role |
What they typically supply in the I-123 category |
Coverage |
| Cardinal Health |
Distribution and nuclear medicine supply chain |
I-123 radiopharmaceutical supply and distribution to sites |
US-centric |
| Curium |
Radiopharmaceutical production and supply |
I-123 branded radiopharmaceutical portfolio |
Global footprint via partners |
| GE HealthCare |
Nuclear imaging/radiopharmacy ecosystem |
I-123 supply through radiopharmacy and distribution channels |
Global |
| IBA (Ion Beam Applications) |
Radioisotope production ecosystem |
Infrastructure and systems for radioisotope production used in nuclear medicine supply chains |
Systems and production enablement |
| Lantheus |
Radiopharmaceutical manufacturer/supplier |
Nuclear medicine products that include the I-123 ecosystem via production and radiopharmacy supply |
US-centric with global distribution |
| Eckert & Ziegler |
Radioisotope producer/distributor |
Iodine-123 supply via isotope production and distribution networks |
Global |
Source basis: Supplier involvement in iodine-123 supply chains is supported by each company’s publicly described role in nuclear medicine radiopharmaceuticals and radioisotopes (see citations [1]-[7]).
How do supplier channels work in practice for “Sodium Iodide I-123”?
Sodium iodide I-123 is not sold like a standard bulk chemical. It is handled under radionuclide supply regulations, with delivery synchronized to activity decay and site receiving capabilities. Most customers therefore buy through distributors or radiopharmacy suppliers that can provide packaged, activity-labeled product and documentation.
Typical operational routing looks like this:
- Radioisotope production (iodine-123 is made via cyclotron target processing and chemical separation)
- Formulation and kit preparation (where applicable) or direct radiopharmaceutical filling
- Activity assignment and shipment scheduling (packing, labeling, and chain-of-custody)
- End-user delivery (nuclear medicine departments, imaging centers)
In this structure, the companies that matter to procurement are those that ship clinically ready sodium iodide I-123 to hospitals and imaging providers.
What procurement-ready supplier list should buyers use?
Use the following supplier set as the starting point for RFQs and conversion planning for sodium iodide I-123 procurement:
- Cardinal Health
- Curium
- GE HealthCare
- Lantheus
- Eckert & Ziegler
- Local/national radiopharmacy distribution partners tied to the above networks
This list reflects entities with active nuclear medicine/radioisotope supply operations and distribution footprints that cover I-123-category sourcing (see citations [1]-[7]).
What supplier selection criteria drive availability for I-123?
Procurement and risk teams normally prioritize:
- Shipment reliability by decay day window (ability to consistently deliver on the targeted activity)
- Regulatory documentation completeness (chain-of-custody, activity and release paperwork)
- Cold-chain and radiation-safe packaging competence
- Allocation behavior during supply constraints
The suppliers listed above are structured to support these requirements through radionuclide logistics and radiopharmaceutical supply operations (see citations [1]-[7]).
Key Takeaways
- Sodium iodide I-123 is sourced through radiopharmaceutical and radioisotope supply chains, not typical chemical bulk suppliers.
- The most actionable supplier list for procurement starts with Cardinal Health, Curium, GE HealthCare, Lantheus, and Eckert & Ziegler, supported by their nuclear medicine distribution networks.
- Supplier selection hinges on delivery timing vs radioactive decay, regulatory documentation, and radionuclide logistics capability.
FAQs
-
Are there non-radiopharmacy suppliers that sell sodium iodide I-123 as a chemical?
No; the clinically used product is supplied via radionuclide-capable distribution and radiopharmacy networks tied to I-123 isotope supply.
-
What determines which company a hospital can buy sodium iodide I-123 from?
The company’s ability to ship clinically labeled activity on schedule, with required regulatory documentation and radionuclide-safe packaging.
-
Do radiopharmaceutical distributors rely on single upstream isotope producers?
Supply can involve multiple upstream sources depending on availability and allocation, but hospital-level purchasing is typically made through established distributor or radiopharmacy partners.
-
Is I-123 supply global, or country-specific?
Both: isotope production is international, while distribution and delivery coverage depend on country-specific licensing and radiopharmacy infrastructure.
-
What is the most common reason for sodium iodide I-123 procurement failures?
Mismatch between shipment timing and activity decay window, often compounded by allocation during supply constraints.
References
[1] Cardinal Health. (n.d.). Company information and health solutions (including radiopharmacy distribution). Cardinal Health. https://www.cardinalhealth.com/
[2] Curium. (n.d.). Radiopharmaceuticals and nuclear medicine product portfolio. Curium. https://www.curiumpharma.com/
[3] GE HealthCare. (n.d.). Nuclear medicine and radiopharmaceutical ecosystem information. GE HealthCare. https://www.gehealthcare.com/
[4] Lantheus. (n.d.). Radiopharmaceuticals and nuclear imaging products. Lantheus. https://www.lantheus.com/
[5] Eckert & Ziegler. (n.d.). Radioisotopes and nuclear medicine production and supply. Eckert & Ziegler. https://www.ezag.com/
[6] IBA. (n.d.). Ion beam applications for radioisotope production systems. IBA. https://www.iba-worldwide.com/
[7] International Atomic Energy Agency. (n.d.). Radioisotopes and related applications in nuclear medicine (general supply context). IAEA. https://www.iaea.org/
